Paper · 2026 · Open access

Pharmacogenomics in Personalized Therapy: How Genetic Testing is Redefining Drug Safety and Efficacy

Nithin Ganesh Ghorpade, Eshveen Kour Sodhi, Gagan D Urs, Balaji Sathyanarayana Gupta, Shilpa Palaksha, Mahabaleshwar Mamadapur

Zenodo (CERN European Organization for Nuclear Research) · Published 25 October 2026 · DOI 10.5281/zenodo.23631730

Open full textCite this paper

In brief

“Pharmacogenomics in Personalized Therapy: How Genetic Testing is Redefining Drug Safety and Efficacy” is a 2026 paper by Nithin Ganesh Ghorpade and 5 co-authors, published in Zenodo (CERN European Organization for Nuclear Research). OpenAlex counts 0 citations as of 21 November 2026. It is open access under a CC BY licence: the full text is free to read at Zenodo (CERN European Organization for Nuclear Research).

Citations
0
Authors
6

Abstract

Background The field of pharmacogenomics (PGx) deals with the study of the impact of genetic variability on drug responsiveness. PGx serves as the scientific backbone of personalized medicine, providing clinicians with the ability to choose appropriate treatments for patients in accordance with their genetic make-up, thus minimizing the risk of adverse drug events (ADEs). Objective To present a systematic review of the scientific evidence on the scientific basis, clinical utility, safety considerations, barriers to implementation, and the future of pharmacogenomics across various medical fields. Methods Narrative review of peer-reviewed articles written between 2000 and 2024, from such databases as PubMed, Scopus, Embase, Web of Science, and Google Scholar. Results Clinical variation in drug metabolism is caused by polymorphisms in the genes that code for CYP450 enzymes (CYP2D6, CYP2C19, CYP2C9) and other pharmaco genes. Several important gene/drug combinations such as CYP2C19/clopidogrel, VKORC1CYP2C9/warfarin, HLA-B*57:01/abacavir, CYP3A5/tacrolimus, and TPMT/azathioprine have CPIC-approved guidelines for pharmacogenomics. PGx-based prescriptions reduce the need for trial and error, reduce ADR frequency, and improve treatment efficacy in oncology, psychiatry, cardiology, infectious disease management, and transplantation. The recognition by the regulatory authorities is increasing, with FDA including PGx biomarkers in the label of hundreds of drugs. Some challenges that exist include lack of clinician education, absence of standard guidelines, lack of EHR integration and ethical issues regarding genetic privacy and discrimination. Conclusion Pharmacogenomics is changing the approach to medication prescriptions from one based on populations towards individually-tailored genetic prescriptions. Integration into clinical practice, along with AI, EHR, and standardized guidelines will be necessary. Keywords Precision Medicine, Pharmacogenetics, Molecular Targeted Therapy, Electronic Health Records, Drug Prescriptions

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Ghorpade, N. G., Sodhi, E. K., Urs, G. D., Gupta, B. S., Palaksha, S., & Mamadapur, M. (2026). Pharmacogenomics in Personalized Therapy: How Genetic Testing is Redefining Drug Safety and Efficacy. Zenodo (CERN European Organization for Nuclear Research). https://doi.org/10.5281/zenodo.23631730

MLA 9

Ghorpade, Nithin Ganesh, et al. “Pharmacogenomics in Personalized Therapy: How Genetic Testing is Redefining Drug Safety and Efficacy.” Zenodo (CERN European Organization for Nuclear Research), 2026. https://doi.org/10.5281/zenodo.23631730.

Chicago

Ghorpade, Nithin Ganesh, Eshveen Kour Sodhi, Gagan D Urs, Balaji Sathyanarayana Gupta, Shilpa Palaksha, and Mahabaleshwar Mamadapur. 2026. “Pharmacogenomics in Personalized Therapy: How Genetic Testing is Redefining Drug Safety and Efficacy.” Zenodo (CERN European Organization for Nuclear Research). https://doi.org/10.5281/zenodo.23631730.

Harvard

Ghorpade, N. G. et al. (2026) ‘Pharmacogenomics in Personalized Therapy: How Genetic Testing is Redefining Drug Safety and Efficacy’, Zenodo (CERN European Organization for Nuclear Research). doi:10.5281/zenodo.23631730.

IEEE

N. G. Ghorpade, E. K. Sodhi, G. D. Urs, B. S. Gupta, S. Palaksha, and M. Mamadapur, “Pharmacogenomics in Personalized Therapy: How Genetic Testing is Redefining Drug Safety and Efficacy,” Zenodo (CERN European Organization for Nuclear Research), 2026, doi: 10.5281/zenodo.23631730.

BibTeX

@article{ghorpade2026pharmacogenomics,
  title     = {{Pharmacogenomics in Personalized Therapy: How Genetic Testing is Redefining Drug Safety and Efficacy}},
  author    = {Ghorpade, Nithin Ganesh and Sodhi, Eshveen Kour and Urs, Gagan D and Gupta, Balaji Sathyanarayana and Palaksha, Shilpa and Mamadapur, Mahabaleshwar},
  journal   = {Zenodo (CERN European Organization for Nuclear Research)},
  year      = {2026},
  doi       = {10.5281/zenodo.23631730},
  url       = {https://doi.org/10.5281/zenodo.23631730}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism

  • pharmacogenomics
  • personalized medicine
  • genetic testing
  • adverse drug reactions
  • drug metabolism
  • cytochrome P450
  • CYP2C19
  • CYP2D6

Work with this paper

Most-cited papers in Pharmacology, Toxicology and Pharmaceutics

All highly cited Pharmacology, Toxicology and Pharmaceutics papers

Questions about this paper

How do I cite this paper in APA style?

Ghorpade, N. G., Sodhi, E. K., Urs, G. D., Gupta, B. S., Palaksha, S., & Mamadapur, M. (2026). Pharmacogenomics in Personalized Therapy: How Genetic Testing is Redefining Drug Safety and Efficacy. Zenodo (CERN European Organization for Nuclear Research). https://doi.org/10.5281/zenodo.23631730

How many times has this paper been cited?

0 times, according to OpenAlex on 21 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Zenodo (CERN European Organization for Nuclear Research): sign in and open the full text from this page.

Who wrote this paper?

Nithin Ganesh Ghorpade, Eshveen Kour Sodhi, Gagan D Urs, Balaji Sathyanarayana Gupta, Shilpa Palaksha, Mahabaleshwar Mamadapur.

What is the DOI of this paper?

10.5281/zenodo.23631730, permanently at https://doi.org/10.5281/zenodo.23631730. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 21 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.